Keywords: Boehringer Ingelhei, Linagliptin, Novo Nordisk, Degludec, Merck & Co, Januvia, EASD, Type 2 diabetes

New data on Boehringer Ingelheim’s linagliptin, Novo Nordisk’s degludec and Merck & Co’s Januvia presented at EASD

Article | 23 September 2010

Print This

New Phase III data presented this week at the 46th Annual Meeting of the European Association for the Study of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in